RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
With recent product approvals and the development of new chemistries and delivery technologies, the RNA-based drugs sector is undergoing rapid change, and UK-based Silence Therapeutics is aiming to be part of that evolution.
You may also be interested in...
The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.
Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.
Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.